Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation
NCT05009329Phase 2Active, not recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glecirasib in solid tumor, non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Jul 2021; status: active, not recruiting.
02
Drugs
glecirasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05009329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009329.